肝损伤血清标志物研究进展*

doi:10.3969/j.issn.1672-5069.2017.02.038

摘要/Abstract

摘要： 肝损伤的临床表现和病理变化较为复杂。准确而可靠的生物学标志物对肝损伤的预防、诊断和治疗都有很大的帮助。目前临床上，肝损伤的诊断主要依赖于各种血清学指标，不同类型的肝损伤血清指标都有相应的异常变化。本文结合国内外肝损伤领域的新近研究进展，对一些传统的酶学标志物，如丙氨酸氨基转移酶、天冬氨酸氨基转移酶、碱性磷酸酶、胆红素、白蛋白、透明质酸等大分子物质以及新型的酶学、分子生物学和病理生理学标志物予以介绍。

关键词: 肝损伤, 血清标志物, 进展

Abstract: Liver injury generally refers to reversible or irreversible damage to the liver cells caused by a kinds of factors. Its clinical manifesation and pathological changes are very complicated. Accurate and reliable biomarkers of liver injuries will offer help for the prevention，diagnosis and therapy for this entity. In clinical practice，the diagnosis of liver disease depends on various serological indicators. This paper summarizes recent research progress in the field of liver damage，enzymology of some traditional markers such as alanine aminotransferase，aspartate aminotransferase，alkaline phosphatase and bilirubin，albumin，hyaluronic acid and other macromolecular substances and new type of enzymology， molecular biology and pathophysiology markers will be reviewed.

Key words: Liver injuries, Serum biomarkers, Progress

雷玮，王丹丹综述，葛广波，孙杰审校. 肝损伤血清标志物研究进展*[J]. 实用肝脏病杂志, 2017, 20(2): 252-254.

Lei Wei，Wang Dandan，Ge Guangb，et al.. Serum biomarkers of liver injury[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 252-254.

参考文献

[1] Shiota G，Kanki K. Retinoids and their target genes in liver functions and diseases. J Gastroenterol Hepatol，2013，28 （Suppl 1）:33-37.
[2] Hoekstra LT，de Graaf W，Nibourg GA，et al. Physiological and biochemical basis of clinical liver function tests: areview. Ann Surg，2013，257（1）:27-36.
[3] Gómez-Lechón MJ，Tolosa L，Donato MT. Metabolic activation and drug-induced liver injury:in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol，2016，36（6）:752-768.
[4] Stine JG，Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury:a systematic review. Expert Rev Gastroenterol Hepatol，2016，10（4）:517-536. [5] Shasthry SM，Sarin SK. New treatment options for alcoholic hepatitis.World J Gastroenterol，2016，22（15）:3892-3906.
[6] Hardy T，Wells C，Kendrick S，et al. White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers. BMC Gastroenterol，2013，13（1）:55.
[7] Ross B，Tran T，Bhattacharya P，et al. Application of NMR spectroscopy in medicinal chemistry and drug discovery. Curr Top Med Chem，2011，11（1）:93-114.
[8] 浦仕彪. 基于代谢组学的自身免疫性肝炎生物标志物筛查及中药干预研究. 成都中医药学报，2013，3（1）：3-5.
[9] O'Shea RS，Dasarathy S，McCullough AJ，et al. Alcoholic liver disease. Hepatology，2010，51（1）:307-328.
[10] Kubo S，Matsuzaki K，Seki T，et al. Severe acute hepatitis in a printing company worker:a case study. J Occup Health，2015，57（1）:87-90.
[11] Lammers WJ，van Buuren HR，Hirschfield GM，et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis:an international follow-up study.Gastroenterology，2014，147（6）:1338-1349.
[12] Fontana RJ，Hayashi PH，Barnhart H，et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.Am J Gastroenterol，2015，110（10）:1450-1459.
[13] Everhart JE，Wright EC. Association of γ-glutamyl transferase（GGT） activity with treatment and clinical outcomes in chronic hepatitis C （HCV）. Hepatology，2013，57（5）:1725-1733.
[14] Caccialanza R，Palladini G，Klersy C，et al. Serum prealbumin: an independent marker of short-term energy intake in the presence of multiple-organ disease involvement. Nutrition，2013， 29（3）:580-582.
[15] Istaces N，Gulbis B. Study of fibro test and hyaluronic acid biological variation in healthy volunteers and comparison of serumhyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals.Clin Biochem，2015，48（10-11）:652-657.
[16] Costelloe SJ，Theocharidou E，Tsochatzis E，et al. Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology. Eur J Gastroenterol Hepatol，2015，27（3）:313-320.
[17] Valva P，Ríos DA，De Matteo E，et al. Chronic hepatitis C?virus infection:serum biomarkers in predicting liver damage.World J Gastroenterol，2016，22（4）:1367-1381.
[18] 余敏. 血清TGF-β、IL-17水平与乙型肝炎纤维化进展关系的研究. 中国肝脏病杂志（电子版），2015，7（1）.
[19] 刘婷，徐铭益. 肝纤维化的血清学诊断研究进展. 实用肝脏病杂志，2016，19（1）：125-128.
[20] Schomaker S1，Warner R，Bock J，et al. Assessment of emerging biomarkers of liver injury in human subjects.Toxicol Sci， 2013， 32（2）:276-283.
[21] Sun C，Chen P，Chen Q，et al. Serum paraoxonase 1 heteroplasmon，a fucosylated，and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. Acta Biochim Biophys Sin（Shanghai），2012，44（9）:765-773.
[22] Pyati AK，Halappa CK，Pyati SA，et al. Serum basal paraoxonase 1 activity as an additional liver function test for the evaluation of patients with cronic hepatitis. J Clin Diagn Res，2015，9（11）:BC12-5.
[23] Yamazaki M，Miyake M，Sato H，et al. Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol Appl Pharmacol， 2013， 268（1）:79-89.
[24] Luo L，Schomaker S，Houle C，et al. Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents.Toxicol Sci，2014，137（1）:12-25.
[25] Bechmann LP，Kocabayoglu P，Sowa JP，et al. Free fatty acids repress small heterodimer partner（SHP） activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.Hepatology，2013，57（4）:1394-1406.
[26] Yang X，Weng Z，Mendrick DL，et al. Circulating extracellular vesicles as a potential source of new biomarkers of drug-induced liver injury. Toxicol Lett，2014，225（3）:401-406.
[27] Arrese M，Eguchi A，Feldstein AE. Circulating microRNAs:emerging biomarkers of liver disease. Semin Liver Dis，2015，35（1）:43-54.
[28] Kondo Y，Kimura O，Shimosegawa T. Significant biomarkers for the management of hepatocellular carcinoma. Clin J Gastroenterol，2015， 8（3）:109-115.
[29] Wang J，Chen J，Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol，2016，231（1）:25-30.
[30] 王毅，杨振华. miR-RNAs 在HBV感染及肝癌发病中的作用.实用肝脏病杂志，2016，19（3）:381-384.
[31] Starckx S1，Batheja A，Verheyen GR，et al. Evaluation of mir-122 and other biomarkers in distinct acute liver injury in rats. Toxicol Pathol，2013，41（5）:795-804.
[32] Starkey Lewis PJ，Dear J，Platt V，et al. Circulating microRNAs as potential markers of human drug-induced?liver injury.Hepatology，2011，54（5）:1767-1776.
[33] Roderburg C，Benz F，Vargas Cardenas D，et al. Elevated mir-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int，2015，35（4）:1172-1184.
[34] 汤纳平，王雁，马璟，等. 血浆miR-122作为药源性肝损伤生物标志物的研究及应用.中国药理学与毒理学杂志，2013，6（3）：481.
[35] Fu Y，Wei X，Tang C，et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.Oncol Lett，2013，6（6）:1811-1815.
[36] Na K，Lee EY，Lee HJ，et al. Human plasma carboxylesterase 1，a novel serologic biomarker candidate for hepatocellular carcinoma.Proteomics，2009，9（16）:3989-3999.
[37] Na K1，Jeong SK，Lee MJ，et al. Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients.Int J Cancer，2013，133（2）:408-415.
[38] Sumer S，Aktug Demir N，K lgelier S，et al. The clinical significance of serum apoptotic cytokeratin 18 neoepitope M30 （CK-18 M30） and matrix metalloproteinase 2（MMP-2） levels in chronic hepatitis B patients with cirrhosis. Hepat Mon，2013，13（6）:e10106.
[39] Vaughn BP，Robson SC，Longhi MS. Purinergic signaling in liver disease. Dig Dis，2014，32（5）:516-524.
[40] 乔靖怡，周璐，金若敏，等. 四氯化碳致大鼠肝损伤早期血清总胆汁酸、α-谷胱甘肽S转移酶、嘌呤核苷磷酸化酶和鸟氨酸氨基甲酰转移酶的变化.中国药理学与毒理学杂志，2013，27（4）:212-214.
[41] Shi Q，Hong H，Senior J，et al. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol，2010，4（2）:225-234.